NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer.
Flawless balance sheet with limited growth.
Share Price & News
How has NewLink Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4NX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 4NX exceeded the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: 4NX exceeded the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is NewLink Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is NewLink Genetics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4NX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4NX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4NX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 4NX is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4NX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4NX is good value based on its PB Ratio (0.8x) compared to the DE Biotechs industry average (3.4x).
How is NewLink Genetics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4NX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4NX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4NX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4NX's revenue (58.9% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: 4NX's revenue (58.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4NX's Return on Equity is forecast to be high in 3 years time
How has NewLink Genetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4NX is currently unprofitable.
Growing Profit Margin: 4NX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4NX is unprofitable, and losses have increased over the past 5 years at a rate of -34.1% per year.
Accelerating Growth: Unable to compare 4NX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4NX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: 4NX has a negative Return on Equity (-52.42%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is NewLink Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: 4NX's short term assets ($102.7M) exceed its short term liabilities ($14.0M).
Long Term Liabilities: 4NX's short term assets ($102.7M) exceed its long term liabilities ($6.2M).
Debt to Equity History and Analysis
Debt Level: 4NX's debt to equity ratio (0.07%) is considered satisfactory.
Reducing Debt: 4NX's debt to equity ratio has reduced from 1.6% to 0.07% over the past 5 years.
Inventory Level: 4NX has a low level of unsold assets or inventory.
Debt Coverage by Assets: 4NX's debt is covered by short term assets (assets are 1769.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4NX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4NX has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 26.3% each year
What is NewLink Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 4NX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 4NX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4NX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4NX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4NX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
What is the CEO of NewLink Genetics's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
NewLink Genetics has no CEO, or we have no data on them.
Management Age and Tenure
Experienced Management: 4NX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Age and Tenure
Experienced Board: 4NX's board of directors are considered experienced (4.5 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mario Mautino (53yo)
Senior VP of Drug Discovery & Intellectual Property Officer
Carl Langren (64yo)
CFO & Principal Accounting Officer
- Tenure: 1.5yrs
- Compensation: US$842.81k
Gene Kennedy (50yo)
Chief Medical Officer
- Tenure: 2.2yrs
- Compensation: US$1.21m
Director of Investor Relations
VP of Finance & Controller
- Tenure: 1.5yrs
- Tenure: 1.5yrs
Lota Zoth (59yo)
- Tenure: 7.2yrs
- Compensation: US$181.13k
Tom Raffin (72yo)
Lead Independent Director
- Compensation: US$204.26k
Matt Sherman (63yo)
- Tenure: 1.7yrs
- Compensation: US$358.92k
Ernest Talarico (48yo)
- Tenure: 21yrs
- Compensation: US$175.00k
Chad Johnson (40yo)
- Tenure: 1.8yrs
- Compensation: US$393.32k
NewLink Genetics Corporation's company bio, employee growth, exchange listings and data sources
- Name: NewLink Genetics Corporation
- Ticker: 4NX
- Exchange: DB
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$76.143m
- Listing Market Cap: US$68.643m
- Shares outstanding: 37.33m
- Website: https://www.newlinkgenetics.com
Number of Employees
- NewLink Genetics Corporation
- 2503 South Loop Drive
- Suite 5100
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NLNK||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 2011|
|4NX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2011|
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/01/18 21:23|
|End of Day Share Price||2020/01/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.